Rolling Out the Next Authorized Generics

「Although authorized generic sales fell below the previous fiscal year, sales of generic drugs rose 3.7% from the previous fiscal year to ¥38,451 million, helped by sales contributions from products launched in 2024 and the impact of selective medical care for long-listed products, among other factors.」

「The company subject to this matter (excluding its authorized generic business) and the businesses operated by the plants subject to this matter are collectively referred to as the “subject business.”」

「Although authorized generic sales fell below the year-earlier level, sales of generic drugs rose 7.2% year on year to ¥16,822 million, helped by sales contributions from products launched in 2024 and the impact of selective medical care for long-listed products, among other factors.」

「The company focused its efforts on addressing stable-supply issues and expanding sales of major products. Generic drug sales rose 1.4% from the previous fiscal year to ¥37,068 million.」

「The company focused its efforts on addressing stable-supply issues and expanding sales, but sales of authorized generics fell below the previous interim consolidated accounting period, resulting in generic drug sales of ¥15,686 million, down 7.2% year on year.」

「While placing maximum emphasis on addressing concerns about stable supply, the Company worked to expand sales of new supplemental listed products. As a result, performance remained above the same period of the previous year, with net sales of ¥26,388 million, up 1.0% year on year.」

「The company focused its efforts on addressing stable-supply issues and expanding sales of newly supplementary-listed products. As a result, sales exceeded the year-earlier level and rose 4.7% year on year to ¥16,895 million.」

「While placing maximum emphasis on addressing issues related to stable supply, results remained above the same period of the previous year, supported by sales of supplemental listed products」

「The performance of 3 AG products, including the authorized generic of Kipres, exceeded the same period of the previous year, while products newly listed for sale in June and December 2021 also contributed, bringing sales to ¥24.855 billion, compared with ¥22.528 billion in the same period of the previous year.」

「In addition to the results of 3 AG products, including Kipres authorized generic (AG), exceeding the previous year's results, sales of the supplemental listed products launched in June 2021 contributed」

「In addition to sales of Kipres authorized generic (AG) and Nasonex AG exceeding the previous year's results, sales of the supplemental listed products launched in June 2021 contributed」

「In addition to increased sales of Nasonex AG, Uritos AG, launched in June 2020, and the supplemental listed products launched during the current fiscal year contributed」

「Sales of the Nasonex AG, launched in August 2019, increased, while the Uritos AG, launched in June 2020, also contributed, bringing sales to ¥14.351 billion, up 1.3% year on year.」

「Sales of the Nasonex authorized generic (AG), launched in August 2019, increased, while the Uritos AG, launched in June 2020, also contributed, bringing sales to ¥7.458 billion, up 2.1% year on year.」

「In promoting its generic drug business by leveraging its strengths, the Company achieved a number of results, including the launch of montelukast AG, the Group's first authorized generic, followed by the launch of mometasone AG and the acquisition of marketing approval for imidafenacin AG.」

「Sales of mometasone, the authorized generic of Nasonex launched in August 2019, contributed, bringing sales to ¥22.038 billion, up 2.8% year on year.」

「Driven primarily by higher sales of mometasone, the authorized generic of Nasonex, sales were ¥14.166 billion, up 4.5% year on year.」

「In addition to maintaining a share of at least 50% within the generic drug market for the authorized generic of montelukast (Kipres), launched in fiscal 2016, the Company will promote the rollout of the next AG products.」

「Going forward, the Company will promote the rollout of the next AG products.」

「In addition to promoting the next phase of AGs, the Company aims to strengthen its formulation development capabilities for generic drugs and increase the number of attractive products developed in-house at the research institute.」

「Having launched montelukast AG during the fiscal year, we began the Group’s initiatives in authorized generics. Going forward, we will promote the rollout of the next authorized generics.」